With regards to genetic alterations, most clinical studies suggest that NSCLC with TP53 alterations have worse prognosis30 and RASA1 is a recognized strong driver of NSCLC and coherently, we found these genes more frequently altered in low MAA samples. This evidence concerns the gene RASA1 and non-small cell lung carcinoma.